Dr. Martin on MRD Status in Multiple Myeloma

Thomas G. Martin, MD
Published: Tuesday, Dec 04, 2018



Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses minimal residual disease (MRD) status in multiple myeloma.

MRD testing is commonly being done at academic institutions. At UCSF, physicians have been doing it for the past 2 to 5 years and have a good track record with doing next-generation sequencing for MRD testing, says Martin.

However, Martin explains that it is only being used to assess prognosis. Physicians are not making treatment decisions based on MRD status. It is known that patients who achieve an MRD-negative state have a longer progression-free survival, and for that reason, MRD serves as a prognostic marker. In terms of treatment, physicians do not yet know what to do with this information. For example, whether physicians should not give maintenance, or potentially shorten maintenance. Martin believes this will be addressed in future clinical trials, as many ongoing clinical trials are using this as an endpoint.
SELECTED
LANGUAGE


Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses minimal residual disease (MRD) status in multiple myeloma.

MRD testing is commonly being done at academic institutions. At UCSF, physicians have been doing it for the past 2 to 5 years and have a good track record with doing next-generation sequencing for MRD testing, says Martin.

However, Martin explains that it is only being used to assess prognosis. Physicians are not making treatment decisions based on MRD status. It is known that patients who achieve an MRD-negative state have a longer progression-free survival, and for that reason, MRD serves as a prognostic marker. In terms of treatment, physicians do not yet know what to do with this information. For example, whether physicians should not give maintenance, or potentially shorten maintenance. Martin believes this will be addressed in future clinical trials, as many ongoing clinical trials are using this as an endpoint.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x